Related Experiment Videos
[Detection of BRAF V600E mutation in metastatic colorectal carcinoma : A QuIP round robin test]
Korinna Jöhrens1, Josephine Fischer2, Markus Möbs3
1Institut für Pathologie, Universitätsklinikum Carl Gustav Carus, TU Dresden, Dresden, Deutschland.
Abstract:
Round robin testing is an important instrument for quality assurance. Increasingly, this also applies to the results of molecular diagnostics in pathology, which directly influence therapy decisions in precision oncology. In metastatic colorectal carcinoma (mCRC), the focus has been on detecting KRAS and NRAS mutations, whose absence allows therapy with EGFR blocking antibodies. Recently, BRAF has been added as another predictive marker, since mCRC patients with BRAF V600E mutation benefit significantly from treatment with encorafenib (a BRAF inhibitor) in combination with cetuximab (anti-EGFR antibody) after systemic therapy. Due to the approval of this treatment in 2020, it is a pre-requisite that BRAF V600E mutation detection in diagnostic pathologies is reliably performed. Therefore, this round robin test with BRAF V600E testing either by immunohistochemistry or molecular methods was performed. The round robin test results demonstrate that molecular BRAF V600E detection is currently clearly superior to immunohistochemical detection.
Insights
Quality assurance in molecular diagnostics is crucial for cancer therapy decisions. A round robin test found molecular BRAF V600E detection superior to immunohistochemistry for metastatic colorectal carcinoma patients.
Area of Science:
- Oncology
- Pathology
- Molecular Diagnostics
Background:
- Precision oncology relies on accurate molecular diagnostics for targeted therapy selection.
- KRAS/NRAS mutation status guides EGFR antibody therapy in metastatic colorectal carcinoma (mCRC).
- BRAF V600E mutation is a key predictive marker for targeted therapy in mCRC.
Purpose of the Study:
- To evaluate the reliability of BRAF V600E mutation detection methods.
- To compare immunohistochemistry (IHC) and molecular testing for BRAF V600E in mCRC.
- To ensure accurate diagnostic pathology for emerging targeted therapies.
Main Methods:
- A round robin testing approach was employed.
- BRAF V600E detection was performed using both immunohistochemistry and molecular methods.
- Results were analyzed to assess diagnostic accuracy and consistency.
Main Results:
- Molecular BRAF V600E detection demonstrated superior performance compared to immunohistochemistry.
- The study identified significant differences in the reliability of the two methods.
- Consistent and accurate detection is critical for patient treatment stratification.
Conclusions:
- Molecular testing is the preferred method for BRAF V600E detection in diagnostic pathology.
- Reliable BRAF V600E testing is essential for guiding BRAF inhibitor combination therapy in mCRC.
- Quality assurance through methods like round robin testing is vital for molecular diagnostics.